- Home
- MRSN vs NMS Comparison
MRSN vs NMS Comparison
Compare MRSN & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- NMS
- Stock Information
- Founded
- MRSN 2001
- NMS 1993
- Country
- MRSN United States
- NMS United States
- Employees
- MRSN N/A
- NMS N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- NMS Finance Companies
- Sector
- MRSN Health Care
- NMS Finance
- Exchange
- MRSN Nasdaq
- NMS Nasdaq
- Market Cap
- MRSN 71.9M
- NMS 71.8M
- IPO Year
- MRSN 2017
- NMS N/A
- Fundamental
- Price
- MRSN $0.53
- NMS $12.44
- Analyst Decision
- MRSN Buy
- NMS
- Analyst Count
- MRSN 7
- NMS 0
- Target Price
- MRSN $6.00
- NMS N/A
- AVG Volume (30 Days)
- MRSN 5.4M
- NMS 12.0K
- Earning Date
- MRSN 03-07-2025
- NMS 01-01-0001
- Dividend Yield
- MRSN N/A
- NMS 4.11%
- EPS Growth
- MRSN N/A
- NMS N/A
- EPS
- MRSN N/A
- NMS N/A
- Revenue
- MRSN $34,837,000.00
- NMS N/A
- Revenue This Year
- MRSN N/A
- NMS N/A
- Revenue Next Year
- MRSN N/A
- NMS N/A
- P/E Ratio
- MRSN N/A
- NMS N/A
- Revenue Growth
- MRSN N/A
- NMS N/A
- 52 Week Low
- MRSN $0.49
- NMS $9.21
- 52 Week High
- MRSN $6.28
- NMS $12.18
- Technical
- Relative Strength Index (RSI)
- MRSN 32.86
- NMS 51.03
- Support Level
- MRSN $0.56
- NMS $12.36
- Resistance Level
- MRSN $0.82
- NMS $12.60
- Average True Range (ATR)
- MRSN 0.07
- NMS 0.07
- MACD
- MRSN 0.03
- NMS 0.01
- Stochastic Oscillator
- MRSN 8.39
- NMS 38.46
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.